Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

NCT03467152 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

326

Enrollment

INDUSTRY

Sponsor class

Conditions

Dementia With Lewy Bodies

Interventions

DRUG: Irsenontrine
DRUG: Placebo

Sponsor

Eisai Inc.